Skip to content
DataLookout
Menu

TOM-HFNCT07016815

Accelerated Optimization of Foundational Medical Therapy in Acute Decompensation of Heart Failure by Telemonitoring: A Pragmatic Multi-center Randomized and Cost-Effectiveness Study

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment increased: 80 → 126 participants Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Start date: Jun 1, 2025 to Jan 1, 2027
    • Eligibility criteria expanded, about 17 words
    • Trial sites expanded: 2 → 8 locations
    • Secondary endpoints: 8 to 10
    • Study description expanded, about 41 words
    • Study title expanded, about 10 words
  2. Minor Site details revised at 2 of 2 sitesv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The proportion of patients achieving left ventricular reverse remodeling (LVRR) at 90 days.
Timeframe: 90 days

Secondary (10)

modified Heart Failure Collaboratory (mHFC) score at 90 days
Difference in New York Heart Association (NYHA) functional class
Composite adherence rate
Difference in 6 minutes' walk test
Difference in heart failure related quality of life measure (by EQ-5D questionnaire)
Show 5 moreShow less
Difference in NT-proBNP level at 90 days
Safety Events
Heart failure (HF) related Hospitalization
Heart failure (HF) related mortality and all-cause mortality
System Usability Scale (SUS)

Arms and interventions

Intervention groupExperimental

Participants assigned to the intervention arm will receive brief training on the use of the telemonitoring device and the TOM-HF application, confined within the first 4 weeks. Heart failure medication will be initiated at the lowest available dose before discharge unless considered clinically inappropriate by the site PI. The core intervention is an accelerated, protocolized remote medication titration process integrating daily biometric and clinical information. Medication titration will be considered every Medication titration will be considered every 1-2 days during the first 4 weeks, according to a prespecified guideline-based algorithm and the patient's physiological data. Medication instructions will be delivered through a closed-loop process: incorporating in-app medication display, push notifications, and patient acknowledgement. Renal function and electrolytes will be tested at affiliated community blood taking centers, with the result reviewed remotely by the study team.

Control GroupNo intervention

Participants randomized to the control arm will receive the same telemonitoring device and mobile application but will not undergo protocolized remote medication titration. Medication titration will instead be performed during scheduled specialist HF clinic at 4-6 weeks intervals at the discretion of the treating physicians, following the same guideline-based treatment framework as in the intervention arm.

Devices: Wearable wrist heart rate and activity monitor, Bluetooth enabled body weight scale with bioimpedance analysis, Bluetooth enabled electronic blood pressure device, mobile application

Sites

8 sites in 1 country